Illumina (ILMN) stock recovered Thursday after the company torched its outlook on company-specific and macro headwinds. In midday trades, ILMN stock sank back below its 50-day line.
X
Illumina is a leader in using next-generation sequencing to “read” the human genome, a key technology as genetic and precision medicines gain steam.
ILMN Stock Recovers After Torching Its 2023 Outlook As 'Huge Accomplishment' Drives Shares comes via ChinaTechNews.com.